It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite evident regulatory roles of heparan sulfate (HS) saccharides in numerous biological processes, definitive information on the bioactive sequences of these polymers is lacking, with only a handful of natural structures sequenced to date. Here, we develop a “Shotgun” Ion Mobility Mass Spectrometry Sequencing (SIMMS2) method in which intact HS saccharides are dissociated in an ion mobility mass spectrometer and collision cross section values of fragments measured. Matching of data for intact and fragment ions against known values for 36 fully defined HS saccharide structures (from di- to decasaccharides) permits unambiguous sequence determination of validated standards and unknown natural saccharides, notably including variants with 3O-sulfate groups. SIMMS2 analysis of two fibroblast growth factor-inhibiting hexasaccharides identified from a HS oligosaccharide library screen demonstrates that the approach allows elucidation of structure-activity relationships. SIMMS2 thus overcomes the bottleneck for decoding the informational content of functional HS motifs which is crucial for their future biomedical exploitation.
Heparan sulfates (HS) contain functionally relevant structural motifs, but determining their monosaccharide sequence remains challenging. Here, the authors develop an ion mobility mass spectrometry-based method that allows unambiguous characterization of HS sequences and structure-activity relationships.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 University of Copenhagen, Copenhagen Center for Glycomics, Department of Cellular & Molecular Medicine, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X); University of Liverpool, Centre for Glycobiology, Department of Biochemistry, Institute of Integrative Biology, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); University of Oxford, Old Road Campus Research Building, Laboratory of Cancer Biology, Department of Oncology, Medical Sciences Division, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 University of Liverpool, Centre for Glycobiology, Department of Biochemistry, Institute of Integrative Biology, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); Keele University, Institute for Science and Technology in Medicine, School of Medicine, Keele, UK (GRID:grid.9757.c) (ISNI:0000 0004 0415 6205)
3 Ferrier Research Institute, Victoria University of Wellington, 69 Gracefield Road, Gracefield, Lower Hutt, New Zealand (GRID:grid.267827.e) (ISNI:0000 0001 2292 3111)
4 University of North Carolina, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, Chapel Hill, USA (GRID:grid.410711.2) (ISNI:0000 0001 1034 1720)
5 University of Georgia, Complex Carbohydrate Research Center, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X)
6 University of Georgia, Complex Carbohydrate Research Center, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X); Utrecht University, Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Science, and Bijvoet Center for Biomolecular Research, Utrecht, The Netherlands (GRID:grid.5477.1) (ISNI:0000000120346234)
7 Freie Universitaet Berlin, Institute of Chemistry and Biochemistry, Berlin, Germany (GRID:grid.14095.39) (ISNI:0000 0000 9116 4836); Fritz Haber Institute of the Max Planck Society, Berlin, Germany (GRID:grid.418028.7) (ISNI:0000 0001 0565 1775)
8 University of Gothenburg, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
9 University of Copenhagen, Copenhagen Center for Glycomics, Department of Cellular & Molecular Medicine, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X); University of Liverpool, Centre for Glycobiology, Department of Biochemistry, Institute of Integrative Biology, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
10 University of Oxford, Department of Chemistry, Chemistry Research Laboratory, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)